NRAS-mutant melanoma: current challenges and future prospect

Figures & data

Table 1 Phase I/II/III trials of MEK inhibitors in NRAS-mutant melanoma

	ORR	PFS	OS
Trametinib^Citation40	22%	4.8 months	81% at 6 months
Binimetinib^Citation44	15%	2.8 months	11 months
Selumetinib^Citation33	5.8%	2.2 months	8 months

Abbreviations: ORR, overall response rate; PFS, progression-free survival; OS, overall survival.

Table 2 Response rate and clinical benefit in patients with NRAS-mutant melanoma receiving immunotherapy

	NRAS-mutant	WT
Anti-PD1-PD-L1
Objective response	64%	35%
Clinical benefit	73%	43%
Ipilimumab
Objective response	19%	11%
Clinical benefit	42%	20%
IL-2
Objective response	33%	26%
Clinical benefit	33%	37%

Abbreviations: WT, wild-type; IL-2, interleukin-2.

FalchookGSLewisKDInfanteJRActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialLancet Oncol201213878278922805292

 PubMed Web of Science ®Google Scholar

DummerRSchadendorfDAsciertoPABinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialLancet Oncol201718443544528284557

 PubMed Web of Science ®Google Scholar

KirkwoodJMBastholtLRobertCPhase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaClin Cancer Res201218255556722048237

 PubMed Web of Science ®Google Scholar